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Transforming Growth Factor-Alpha: A Major Human
Serum Factor that Promotes Human Keratinocyte
Migration
Yong Li1,2, Jianhua Fan1, Mei Chen1, Wei Li1,3 and David T. Woodley1,3
In unwounded skin, human keratinocytes (HKs) are in contact with a plasma filtrate. In an acute wound, HKs
come in contact with serum for the first time. Because human serum (HS), but not plasma, promotes HK
migration, we speculated that a major HK pro-motility factor in vivo comes from serum. In this study, we
compared all of the published growth factors (GFs), reported to promote HK migration, with HS. No single GF
could duplicate the HK pro-motility activity in HS. Among these GFs, tumor growth factor (TGF)a showed the
highest HK pro-motility activity, reaching B80% of the activity in HS. The order of potency was:
TGFa4insulin4EGF4heparin binding (HB)-EGF4IGF-14basic fibroblast growth factor 4IL-84HGF4IL-14
KGF4TGFb. Interestingly, the combination of TGFa and insulin could duplicate the HK pro-motility activity in
HS, although only the TGFa, but not insulin, levels increase in serum over plasma. Addition of neutralizing
antibodies against TGFa to serum or depletion of TGFa from serum by immunoprecipitation significantly
abolished its HK pro-motility activity. Plasma with added TGFa stimulated HK migration that reached more than
80% of the serum stimulation. Since insulin levels are identical between plasma and serum, we propose that
TGFa is the physiologic HK pro-motility factor in HS.
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INTRODUCTION
Re-epithelialization is the process by which human keratino-
cytes (HKs) laterally migrate across the wound bed from the
cut edges of a skin wound and from the cut appendages in the
wound bed to resurface the wound (Martin, 1997; Singer and
Clark, 1999). Basal HKs are destined to differentiate
terminally into the upper layers of the epidermis. When the
skin is acutely wounded, however, these cells experience
serum for the first time and a completely new set of
extracellular matrices (ECMs). The newly created wound
environment converts the resident HKs from terminally
differentiating cells into highly migratory cells. Within the
wound bed, there are fibrin, fibrinogen, fibronectin, and
collagen, as well as a spectrum of soluble cytokines and
growth factors (GFs) largely from serum. Fibronectin and
collagen are two ECMs known to be capable of initiating HK
migration even in the absence of soluble GFs (Li et al.,
2004b). In addition to pro-motility ECMs, certain selected
GFs are also ‘‘motogens’’. However, in contrast to ECMs,
motogenic GFs cannot alone initiate HK migration. For
stimulation of HK migration, HKs must be in contact with a
pro-motility matrix such as collagen or fibronectin. Therefore,
the function of motogenic GFs is to enhance ECM-initiated
cell migration (reviewed by Li et al., 2004a).
Bovine pituitary extract supplemented with a few recom-
binant GFs has long been used as the stimulus of HK
migration and proliferation in cell cultures, growth assays,
and motility assays. However, in real life, human skin cells
are never in contact with bovine pituitary extract. Therefore,
bovine pituitary extract is not physiologically relevant. Eleven
purified recombinant GFs and cytokines have been reported
to stimulate various degrees of HK migration in vitro. These
reported motogenic GFs for HKs include EGF, heparin
binding (HB)-EGF, tumor growth factor (TGF)a, insulin, IGF-1,
basic fibroblast growth factor (FGF), hepatocyte growth factor
(HGF), IL-1a, IL-8, keratinocyte growth factor (KGF)/FGF7,
and TGFb (reviewed by Li et al., 2004a). However, it has
never been studied if any of these factors, alone or in
combination, represents the physiologic pro-motility GF(s) for
HKs in human skin wounds. Human serum (HS) in an acute
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wound provides a major source of soluble factors (Singer and
Clark, 1999). In intact skin, the cells are nourished by plasma
filtered through a vascular basement membrane and a
basement membrane at the dermal–epidermal junction.
When skin is wounded, HKs directly encounter serum for
the first time. We recently showed that HS, but not human
plasma (HP), contains one or more factors that promote HK
migration (Henry et al., 2003). Therefore, the purpose of the
current study was to identify the HK pro-motility factor(s) in
HS. Our approaches were: (a) to compare systematically the
pro-motility activity of all the GFs, previously reported in the
literature to promote HK motility, with HP and HS; (b) to
block or deplete the function of a specific GF(s) in HS with
neutralizing antibodies and verify the importance of the GF
for HK migration; and (c) to add GFs alone or in combination
to HP and test if the addition converts HP to a pro-motility
reagent like HS. We found that TGFa and insulin together
were capable of duplicating the pro-migration activity of HS.
Because the concentrations of insulin are the same in plasma
and serum, while TGFa is only found present in serum, we
concluded that the factor in HS primarily responsible for its
ability to promote HK migration is TGFa.
RESULTS
TGFa shows the highest HK pro-motility activity when
compared with HS
Eleven GFs have been reported in the scientific literature to
either directly or indirectly stimulate HK migration in vitro
(reviewed by Li et al., 2004a). First, we carried out
dose–response analyses to determine the optimal working
concentration that stimulates the maximum HK migration for
each of the 11 GFs. As shown in Figure 1, HK migration on
collagen without any GFs had Migration Indexes (MI)
between 4 and 6 (the starting point). Under these conditions,
five of the 11 GFs, including basic FGF, IL-8, HGF/scatter
factor, IL-1, and KGF/FGF7, showed very modest pro-motility
effects compared with the effect of collagen alone. These GFs
generated MIs between 7 and 8. One GF, TGFb, showed no
detectable stimulating effect at all in the 16-hour migration
assays. In contrast, the remaining five GFs significantly
enhanced HK migration on collagen. These more potent
motogenic GFs included TGFa, insulin, EGF, and IGF-1. In
addition, HB-EGF also showed significant stimulation of HK
migration. Except for insulin, the optimal working concentra-
tions of all the other three GFs fell into the nanogram or
subnanogram range. In contrast, no significant stimulating
effect was detected for insulin below 250 ng/ml. The
optimized concentrations of the 11 GFs for stimulation of
HK migration are summarized in Table 1.
We then compared each of the 11 GFs under their optimal
concentrations with 10% HS for stimulation of HK migration
(no further enhancement of HK migration was detected when
higher percentages of HS were used; data not shown). As
shown in Figure 2a–m, in the control without any soluble
factors, HKs migrated modestly on a collagen matrix (panel
a). The addition of HS, as expected, greatly enhanced HK
migration on collagen (panel b vs. panel a). In comparison,
TGFa, insulin, EGF, HB-EGF, and IGF-1 also promoted HK
migration (panels c, d, e, f, g). In decreasing order of potency,
the pro-motility effects on HKs were TGFa 4 insulin 4 EGF
4 IGF-1. The rest of the GFs or cytokines showed either weak
or insignificant stimulation (panels h, i, j, k, l, m). Figure 2n
shows the migration index (MIs) from each experimental
condition in triplicate from 15 or more nonoverlapping fields
analyzed by a computer. HK migration on collagen alone
produced a mean MI of 571.8 (bar 1). In contrast, 10% HS-
enhanced HK migration on a collagen matrix generated a
mean MI of 2371.5 (bar 2). The addition of TGFa, insulin,
IGF-1, HB-EGF, and EGF all greatly increased HK migration
relative to the collagen control. The single asterisk in the
figure show MIs that are significantly different from the
control MI. Nevertheless, none of the 10 factors alone was
able to mimic the full pro-motility effect of serum on HK
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Figure 1. Optimization of reported GFs for HK migration. HKs were
GF-starved overnight (B18 hours) and subjected to colloidal gold migration
assays on type I collagen in the absence or presence of 11 previously reported
GFs that promote HK motility with the indicated concentrations. Except for
insulin in the range of mg/ml, the effective concentrations for all other GFs fell
into the range of ng/ml. Following 16 hours of incubation, the migration was
stopped and measured by computer-assisted quantitative analyses of the
migration tracks, shown as MIs (%) (Materials and Methods). The dose
responses of the MIs to the 10 GFs are shown. This experiment was repeated
three times.
Table 1. Optimized concentrations
Growth
factor
Optimal
conc. (ng/ml)
Growth
factor
Optimal
conc. (ng/ml)
TGFa 10 IL-8 10
Insulin 5,000 HGF 10
EGF 10 IL-1a 10
IGF-1 5 KGF 10
HB-EGF 10 TGFb NA
bFGF 10
bFGF, basic fibroblast growth factor; EGF, epidermal growth factor; HGF,
hepatocyte growth factor; KGF, keratinocyte growth factor; IGF, insulin-
like growth factor; IL, interleukin; TGF, transforming growth factor; NA,
not applicable.
Summary of the dose–response assays shown in Figure 1. The minimum
concentrations that cause the optimal HK motility on collagen.
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migration. All of the GFs used were tested for their biological
activity. Except TGFb, all other GFs stimulated protein
tyrosine phosphorylation and the Thr–x–Tyr phosphorylation
of extracellular signal-regulated protein kinase (ERK)1/2 in
HKs. As expected, TGFb increased phosphorylation of
Smad2/3 (ser-465/467) in HKs (data not shown).
The combined pro-motility effects of TGFa and insulin are equal
to HS
To determine if combinations of the tested GFs could
generate HK migration at the same level as HS, we focused
on TGFa, insulin, IGF-1, EGF, as well as HB-EGF, because
they showed the strongest stimulation of HK migration in our
initial individual GF screening experiments. We compared
the combined effects of double, triple, and quadruple GFs
with the effect of all 10 factors (except HB-EGF) together and
with the effect of HS. As shown in Figure 3a–o, the greatest
cellular motility was induced by the combination of TGFa
and insulin (panel i). The HK migration generated by these
two soluble factors equaled the migration induced by the
presence of all four GFs (panel d) or a combination of TGFa,
insulin, and IGF-1 (panel e). Most importantly, the presence
of TGFa and insulin stimulated HK migration at the same
level as HS (panel b). Quantitation (MIs) of these experiments
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Figure 2. No single GF can replace the pro-motility activity in HS for HKs.
GF-starved HKs were subjected to colloidal gold migration assays on collagen
in the absence or presence of the indicated individual GFs with the optimized
concentrations shown in Table 1, in comparison to the stimulation of 10%
HS. (a–m) Representative photographic images of the migration tracks under
the indicated conditions are shown. (n) The computer-assisted quantitative
analyses of the migration tracks from 15 randomly selected fields are shown
as MIs. This experiment was repeated four times and reproducible results
were obtained. The differences between HS and indicated GFs were
significant, *Po0.001. Differences between collagen alone and rest of the
GFs were insignificant, **P40.2.
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Figure 3. Combination of TGFa and insulin accounts for the full HS effect.
HKs were GF-starved overnight and subjected to colloidal gold migration
assays in the presence of various combinations of TGFa, EGF, HB-EGF,
insulin, and IGF-1, with the optimized concentrations shown in Table 1 or
10% HS. (a–o) Representative images of the migration tracks under
stimulation of the indicated GFs. (p) Computer-assisted quantitative analyses
of the migration tracks are shown as MIs. Note that the minimum combination
of the GFs to replace the full effect of HS is the combined effect of TGFa and
insulin (bars 4, 5, 6, and 9). This experiment was repeated multiple times and
similar results were obtained. The differences between serum and indicated
combinations of GFs were insignificant, *P40.1.
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is shown in Figure 3p. The bars with an asterisk show that the
GF-induced HK migration was not significantly different from
serum-induced migration. Note that only those combinations
that contained both TGFa and insulin showed pro-migratory
activity at levels similar to HS (bars 4, 5, 6, and 9 vs. bar 2). In
contrast, no other combination of the GFs was able to replace
the effect of HS (bars 7, 8, 11, 12, 13, 14, and 15).
Interestingly, the combination of all 10 GFs (except HB-EGF)
also was unable to match the full effect of HS (bar 3). The
reason for this result is unclear (see Discussion). Taken
together, TGFa and insulin is the minimum combination of
previously reported motogenic GFs capable of duplicating
the HK pro-motility effect of HS.
Converting plasma to serum by the addition of TGFa
When the skin is wounded, the resident cells experience an
acute transition of plasma to serum. We have previously
shown that, unlike HS, HP does not stimulate HK migration
(Henry et al., 2003). This observation suggested that HK pro-
motility factor in serum is absent from plasma and is acquired
following the plasma-to-serum transition. Therefore, we
tested whether or not the addition of TGFa back to plasma
would convert plasma to a serum-like reagent and stimulate
HK migration. As shown in Figure 4, the addition of TGFa and
insulin converted plasma to an agent that stimulated HK
migration as effectively as serum (bar 4 vs. bar 2). In contrast,
none of the four individual GFs was able to convert plasma
100% into a serum-like agent that enhances HK motility (bars
5, 6, 7, and 8). The addition of TGFa to plasma, which
contains the same amount of insulin as serum, increased HK
motility to 85% of that of serum (1871.4; bar 3). In contrast,
the addition of EGF to plasma only restored the HK migration
to an MI of 1470.8 or 70% of that of serum (bar 7). Although
the addition of EGF alone to plasma promoted HK motility to
a statistically significant level compared to no addition, the
pro-motility effect was significantly less than that of TGFa,
consistent with our previous report (Cha et al., 1996).
Inhibition of TGFa in HS significantly impairs its ability to
promote HK migration
The results of the above experiments led us to the central
question of whether or not the HK pro-motility effect in HS
was due to TGFa and insulin. To address this question, we
added neutralizing antibodies against human TGFa and
insulin or control Ig molecules (IgG) to HS and tested the
effects of these antibodies on HS-stimulated HK migration.
Additional controls included were neutralizing antibodies
against EGF and IGF-1. As shown in Figure 5a, HS promoted
HK migration on collagen, producing an MI of 2273.7 (bar 2
vs. bar 1). The addition of nonspecific control IgG to HS did
not show any significant effect (bar 3). Note that the ‘‘control
IgG’’ here means normal control IgG molecules from more
than one species, according to the species of the primary
antibodies used. In contrast, the combined addition of all four
antibodies to HS completely abolished the pro-motility effect
of HS on HKs, producing a mean MI of 571.3, similar to the
no HS control (bar 4 vs. bar 1). These experiments indicated
that one or more of the four GFs were responsible for the
pro-motility effect of HS on HKs.
To further narrow down the individual contribution of the
factors, we tested the effects of single, combinations of two,
and combinations of three of the four neutralization
antibodies. We also tested the effect of antibody blocking
HB-EGF in HS. The addition of each of the five antibodies
showed variable inhibition of the HS stimulation of HK
migration (bars 5, 6, 7, 8, and 19). However, among the five
factors, inhibition of TGFa by its corresponding neutralizing
antibody showed the greatest inhibition with MIs of 7.871.6
(bar 5). Furthermore, consistent with previous observations
on the combined effects of TGFa and insulin, the combined
use of anti-TGFa and anti-insulin antibodies were the
minimum requirement for a complete blockade of the pro-
motility effect of HS on HKs. Together, these two neutralizing
antibodies lowered the HK MIs from over 20 (bars 2 and 3) to
6–7 (bars 9, 15, and 16).
HS contains higher levels of functional TGFa and insulin than
the previously reported levels
Previous studies with radioimmune assays (Chakrabarty et al.,
1994; Egesten et al., 1996) and the available ELISA data on
the internet (Quantikine DTGA00, R&D Systems, Inc. at
info@RnDSystems.co.uk; see Table 2 and Discussion) re-
ported inconsistent amounts of either none or subnanograms/
ml of TGFa in HS. However, we could not detect any
significant stimulation of HK migration with less than 2.5 ng/
ml of TGFa under serum-free conditions in vitro. This is
consistent with the data previously published by others and
us (Barrandon and Green, 1987; Cha et al., 1996). We further
investigated this discrepancy. Based on the ND50 of the anti-
TGFa antibody (0.2–0.4 mg/ml of the anti-TGFa antibody for
3 ng/ml of TGF from the R&D Systems, Inc. AF239-NA, Lot,
ANRO1), our data suggest that 3–10 mg/ml of the anti-TGFa
antibody was required to inhibit the effect of 10 ng/ml of
M
ig
ra
tio
n 
in
de
x 
(%
)
5
1 2 3 4 5 6 7 8
10
15
20
25
*
**
**
**
**
Co
ntr
ol HS HP
HP
+T
+
Ins
HP
+In
s
HP
+E
GF
HP
+IG
F-1
HP
+T

Figure 4. Conversion of HP to HS-like reagent by addition of TGFa to
plasma. The optimized concentrations of the indicated GFs were added to HP
and their effects on HK migration were compared with HS. The results shown
here were reproducible in three independent experiments. The differences
between serum and indicated GFs were insignificant, *P40.1. The
differences between plasma alone and plasma plus added GFs were
significant, **Po0.005.
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TGFa used in our migration assays (Figure 5b, bars 2–6).
Therefore, we expected that, to block 0.02 ng/ml of TGFa in
HS, only 2–5 ng/ml of the anti-TGFa antibody would be
required. Surprisingly, we found that 1–3 mg/ml of the anti-
TGFa antibody was required to block serum-stimulated HK
migration (bars 8–12 vs. bar 7). The specificity of the antibody
was confirmed by addition of increasing amounts of TGFa
ligand, which reversed the antibody’s effect (bars 14–17). In
addition, we tested if combined usage of neutralizing
antibodies against TGFa, insulin, EGF, and IGF-1 blocks
serum-stimulated HK migration, with the concentrations
which neutralize the reported levels of these GFs in HS as
shown in Table 2. We did not observe any additional
significant inhibition (data not shown). These data suggest
that the available biochemical measurement of 0.02 ng/ml of
TGFa in HS was significantly less than its functional
concentration. The reason for this discrepancy remains
unknown.
We also tested if the anti-TGFa antibody crossreacts with
other GFs in serum. As shown in Figure 5c, while the addition
of 10 mg/ml of the anti-TGFa antibody completely inhibited
TGFa (10 ng/ml)-stimulated HK migration (bar 3 vs. bar 2), it
did not inhibit HK migration driven by EGF (10 ng/ml) (bars 4
and 5), insulin (5 mg/ml) (bars 6 and 7), IGF-1 (5 ng/ml) (bars 8
and 9) and HB-EGF (10 ng/ml) (bars 10 and 11). Hence, the
inhibition of serum-stimulated HK migration by anti-TGFa
antibody was not due to nonspecific crossreaction of the
antibody with the other factors in HS that promote HK
migration.
Finally, to confirm the pro-motility effects of TGFa and
insulin in HS, we depleted these two factors from HS by anti-
TGFa or anti-insulin antibody immunoprecipitation (Materi-
als and methods). We then used the TGFa-depleted or
insulin-depleted HS in HK migration assays. As shown in
Figure 5d, immunoprecipitation with the anti-TGFa antibody
depleted, in a dose-dependent manner, approximately 80%
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Figure 5. TGFa and insulin are the critical GFs in HS for HK migration. (a) Blockade of TGFa and insulin functions in HS completely eliminates its HK pro-
motility activity. GF-starved HKs were subjected to colloidal gold migration assays on collagen in HS in the absence or presence of control IgG (goat, rabbit, and
mouse were tested) or indicated GF neutralizing antibodies (all with 5 mg/ml). Note that the addition of the anti-TGFa and anti-insulin antibodies completely
eliminated the pro-motility effect of HS. The differences between collagen alone control and indicated neutralizing anti-GF antibodies were significant,
*Po0.001. The differences between collagen alone and the indicated combinations of anti-GF antibodies were insignificant, **P40.05. (b) Requirement for a
similar amount of anti-TGFa neutralizing antibodies to block the HK pro-motility effect of 10 ng/ml of TGFa and 10% of HS. The increasing amounts of anti-
TGFa antibodies were added to migration assays in the absence or presence of either TGFa (10 ng/ml) or 10% HS. The inhibition by anti-TGFa antibodies was
reversed by exogenous addition of indicated concentrations of human recombinant TGFa. The MIs of HK migration are shown. (c) Anti-TGFa antibodies did not
crossreact with other HK pro-motility GFs. HK migration was analyzed in the absence or presence of TGFa, insulin, EGF, HB-EGF, and IGF-1 with the optimized
concentrations shown in Table 1 without or with added anti-TGFa antibodies (10 mg/ml). The MIs of HK migration are shown. (d) Pre-depletion of TGFa or
insulin from HS by immunoprecipitation abolished the expected amount of HK pro-motility effect in HS. 10% HS was first subjected to immunoprecipitation
(see protocol in Materials and methods) with the indicated amounts of either anti-TGFa or anti-insulin antibodies. The ‘‘TGFa- or insulin-depleted’’ HS were used
for HK migration assays. The MIs of HK migration are shown. All above experiments were repeated twice and similar results were obtained.
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of the HK pro-motility activity present in HS (bars 3–6 vs. bar
2). In contrast, addition of a normal goat IgG did not show
any effect (bar 7). The anti-insulin antibody immunoprecipi-
tation also decreased up to 60% of the stimulatory effect in
HS on HK migration (bars 8–11 vs. bar 7). Addition of a
control mouse IgG had little effect (bar 12).
In the colloidal gold cell migration assays, the HKs migrate
as unattached single cells. It was unclear whether TGFa and
insulin would have similar pro-motility effects when HKs
move in sheets as they do in in vivo human wounds.
Therefore, we repeated our experiments using an independent
in vitro wound-scratch assay, where HKs migrate as a
contiguous sheet of cells. As shown in Figure 6, in the
absence of GFs, the HKs migrated modestly on a collagen
matrix (panel b vs. panel a). In the presence of HS, however,
HKs exhibited enhanced migration and completely healed
the ‘‘wounded area’’ (panel c). Consistent with previous
observations, the addition of TGFa and insulin to serum-free
conditions induced complete wound closure like HS (panel d
vs. panel c). Also consistent with previous observations, the
addition of TGFa and insulin to HP transformed plasma into a
serum-like reagent capable of inducing complete in vitro
Table 2. HK pro-motility factors: plasma versus serum
Growth factor In plasma (ng/ml) In serum (ng/ml) S/P ratio Source of ref.
bFGF UD UD NC bFGF IA, R&D
IL-1a UD UD NC IL-1a IA, R&D
KGF UD UD NC KGF IA, R&D
Insulin 0.2–1.08 0.2–1.08 NC Ins IA, ARUP Lab.
HGF 0.787 1.257 ISC HGF IA, R&D
IGF-1 86 105 ISC IGF-1 IA, R&D
TGF-b1 0–2.26 48.6 Inc TGFb1 IA, R&D
TGFa UD 0.022 Inc TGF IA, R&D
EGF 0.013 0.336 Inc EGF IA, R&D
HB-EGF ND ND ND ND
IL-8 0.004 0.012 ISC IL-8 IA, R&D
bFGF, basic fibroblast growth factor; EGF, epidermal growth factor; HGF, hepatocyte growth factor; IA, immunoassay; IGF, insulin-like growth factor; IL,
interleukin; Inc, increase; ISC, insignificant change; KGF, keratinocyte growth factor; NA, not applicable; NC, no change; ND, no data; R&D, R&D Systems,
Inc. (at info@RnDSystems.co.uk); S/P ratio, serum/plasma ratio; TGF, tumor growth factor; UD, undetectable.
ARUP lab at: www.aruplab.com/guides/ug/tests/0070155.jsp.
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Figure 6. TGFa and insulin drive HKs to close the wound in vitro like HS. Twelve-well tissue culture plates were coated with type I collagen (40 mg/ml,
2 hours). Unattached collagens were removed by washing with Hank’s balanced salt solution buffer. GF-starved HKs were plated (250,000 cells/well) in GF-free
medium, so that the HKs’ density reached 90% confluence in each well within 2–3 hours. Standardized ‘‘wounds’’ were made as described previously
(Li et al., 2004a). The media were then changed to fresh serum-free (SF), HS-containing, HP (without or with added GFs)-containing, or the indicated
GF-containing medium. Following incubation for the indicated period of time, the wound closures were photographed and quantitation (Average Gap) was
carried out as described previously (Li et al., 2004a). The results shown here were reproducible in two independent experiments.
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wound closure (panel h vs. panel g). As expected, HKs
migrated modestly on collagen in the absence of any GFs
(panel e vs. panel a), whereas plasma stimulation did not
significantly enhance HK migration (panel f). In contrast, HS
induced complete wound closure (panel g).
DISCUSSION
The impetus for our study was the original observation that
HS, but not HP, promotes HK migration (Henry et al., 2003).
To identify the non-ECM, soluble, and physiologic pro-
motility factor(s) for HKs, we closely examined the factors in
HP and serum. Our strategy was to screen the GFs published
in the scientific literature that stimulate HK migration and
compared them with whole HS. Our results show that none
of the 11 published GFs alone could duplicate the pro-
motility effect of HS. When used as single agents, the GFs that
demonstrated the greatest pro-motility effect (for HKs migrat-
ing on a pro-motility matrix such as collagen) were TGF-a,
EGF, HB-EGF, insulin, and IGF-1. Our second strategy was to
take those GFs that demonstrated the greatest pro-motility
effects and compared the combine effects of these GFs with
HS. While most combinations of GFs could not stimulate HK
motility on collagen to the same level as HS, we found that
the combination of TGFa in the presence of insulin could
duplicate HS’s effect on HK migration. Our third strategy was
to block TGFa and insulin in HS with neutralizing antibodies
and then examine the pro-motility effect of TGFa- and
insulin-depleted HS. We found that inhibition of TGFa and
insulin function in HS completely blocked serum’s pro-
motility effect on HKs. Our final strategy was to add TGFa
and insulin back to plasma and see if this would transform
plasma from a reagent that does not support HK motility into
a pro-motility, serum-like reagent that promotes HK migra-
tion. We found that the addition of TGFa and insulin to
plasma created a reagent that could drive collagen-initiated
HK migration to the same level as HS. Consistently, TGFa is
undetectable in HP, but its level increases significantly in HS.
However, unlike TGFa levels, insulin levels are the same in
plasma and serum (see Table 2). Therefore, we propose that
the increased levels of TGFa in serum are responsible for the
transformation of HKs from non-motile to motile cells in
wounds. A schematic representation of these findings is
shown in Figure 7, which shows that the up- and down-
regulation of TGFa levels during the plasma-to-serum-to-
plasma transition in the wound bed is a major soluble driving
force for HK migration, leading to re-epithelialization of the
wound. Although the precise composition of connective
tissue matrix that is in contact with re-epithelializing HKs is
not known, it does contain type I collagen. Of all of the
known purified ECMs, type I collagen promotes HK migration
the most (Li et al., 2004a).
A surprising observation of our study was the discrepancy
between the reported TGFa and insulin concentrations in HS
and the minimum working concentrations of these GFs
needed for an effect in our in vitro cell migration assays.
Table 2 shows the available data on the measured amounts of
the 10 GFs (except HB-EGF) studied in HP and HS. In
particular, the 0.022 ng/ml of TGFa and the 1 ng/ml of insulin
in HS are several hundred fold lower than the optimized in
vitro working concentrations in our migration assays (see
Table 1). The concentrations used in our study are similar to
the concentrations used in migration studies from several
independent laboratories (Barrandon and Green, 1987; Cha
et al., 1996; Benoliel et al., 1997; Fang et al., 1998).
Therefore, we studied this question by an independent
approach. Instead of using biochemical binding assays, such
as a radioimmunoassay, a radioreceptor assay, or an ELISA
assay, we examined the functional levels of these two GFs in
HS by performing titration analyses of neutralizing antibodies
against TGFa and insulin (see Figure 5b and d). We were
surprised to find that the observed functional concentrations
of TGFa and insulin in HS are virtually equivalent to the
optimized working concentrations that we and other labora-
tories used in in vitro migration assays. Similar observations
have also been made by Nishiyama’s group. They showed
that 30 mg/ml of anti-TGFa antibodies (500-P16, PeproTech
EC, London), which are capable of neutralizing the effect of
more than 5 ng/ml of TGFa, was needed to block even 1%
TGFInsulin
BM
BM
BM
BM
(Plasma)
Acute wound
Inflammation
Re-epithelialization
Tissue remodeling
(Plasma transition to serum)
(Serum)
(Serum back to plasma)
HDMECDFHK
Figure 7. A schematic representation of how TGFa promotes HK migration
during wound healing. The three classical and sequential events of wound
healing, inflammation, re-epithelialization, and tissue remodeling are
schematically depicted in a simplified version. Only three major types of skin
cells, HKs, dermal fibroblasts (DFs), and human dermal microvascular
endothelial cells (HDMECs), are shown as indicated by different colors. The
insulin levels in HS remain unchanged throughout the healing process. In
contrast, the TGFa levels are dramatically increased in the wound fluid,
following the transition from plasma to serum in the wound bed. After the
wound is closed and after transition of serum back to plasma, the levels of
TGFa go back to those in unwounded skin. Possible contributions by other
cell types and matrix components to the skin wound healing are omitted for
the sake of simplicity, but not reality. The relative numbers and proportions
of the various types of cells do not quantitatively reflect the real human
skin cells.
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HS-stimulated induction of laminin-5 production by kerati-
nocytes (Amano et al., 2004). While the reason for the
discrepancy between the functional and biochemical means
remains to be resolved, our data suggest that the previous
measurements of the two GFs in HS may not reflect their
physiological levels. It is also possible that HP or serum
induces keratinocytes to synthesize and secrete ligands, such
as TGFa, that may override the added neutralizing antibodies.
This latter point is supported by previous studies (Pittelkow
et al., 1993; Shvartsman et al., 2001) that suggest that
autocrine mitogens (or motogens) might theoretically be
present at higher than expected local concentrations within
close proximity of the cell colonies (i.e. higher than one
would expect diffused into the total medium volume), thus
requiring higher than expected concentrations of antibody to
neutralize the autocrine GF.
The importance of EGF receptor signaling in HK migration
by the above findings is in accordance with other studies that
have examined GFs that promote HK motility. An early study
by Barrandon and Green (1987) first reported that EGF
enhanced HK migration. Using a HK single-cell assay Chen
et al. (1993) demonstrated directly that EGF was not only a
mitogen for HKs but also a ‘‘motogen’’. In that study, it was
shown that EGF’s early effect on HK cultures was to promote
migration and then later it induced cell division. Ando and
Jensen demonstrated that EGF and IGF I enhanced keratino-
cyte migration (Ando and Jensen, 1993). Later, Cha et al.
(1996) directly compared the pro-migration effect of EGF and
TGFa on HKs. They showed that, of the two GFs, TGFa was a
far more potent pro-motility agent than EGF. TGFa and EGF
both bind to the same receptor on the plasma membrane of
the HK. To this day, it is not clear why TGFa is a superior
motogen to EGF for HK motility. Our study herein is in
accordance with a human wound-healing study by Brown
et al. (1989). These investigators did not use TGFa, which
utilizes the same cell surface receptor with EGF, but rather
topically applied recombinant EGF to acute, split-thickness,
human wounds in 12 subjects. They found that the addition
of topical EGF promoted wound closure over the vehicle
control. However, at that time, recombinant TGFa was not
available and the study by Cha and co-workers showing the
differential motogenic effects between EGF and TGFa had not
yet been published. A clinical study that directly compares
topical EGF and TGFa on human wound closure would be
very interesting. In mice, interestingly, TGFa did not appear
to play a primary role in healing skin wounds. It has been
shown that TGFa knockout mice exhibit normal wound
closure compared with wild-type mice (Luetteke et al., 1993;
Mann et al., 1993; Guo et al., 1996). However, mice heals
wounds in a very different manner than humans. It is known
that murine wounds heal primarily by wound contraction
rather than re-epithelialization (Coulombe, 2003).
What about other GFs that have been reported to promote
HK motility? The effect of TGFb on HK motility remains
controversial (Salo et al., 1991; Decline et al., 2003). Part of
this controversy may be on whether TGFb promotes HKs
directly or whether it does it by a secondary effect via
promoting ECM production and deposition. In support of the
secondary effect is the study by Nickoloff et al. (1988) who
showed that TGFb1 promotes HK migration by inducing
fibronectin production. In our short-term HK migration
assays, we could not detect any pro-motility effect of TGFb.
It is likely that not enough HK-derived pro-motility ECM was
synthesized and deposited in the short time period of the
assays. KGF/FGF7 is a paracrine GF produced by mesench-
ymal cells, which acts on cells of epithelial origin. With
regard to KGF/FGF7 as an HK motogen, Zeigler et al. (1999)
concluded that KGF was a mitogen but not a motogen for
HKs. This is in contrast to the earlier studies (Tsuboi et al.,
1993; Sato et al., 1995; Putnins et al., 1999), which
concluded that KGF was a motogen for HKs. In fact, the
studies of Putnins and Sato both suggested that KGF
stimulates HKs to migrate even without an ECM being
present. An in vivo wound-healing study with KGF knockout
mice, however, showed no impairment of re-epithelialization
(Guo et al., 1996). We tested KGF with and without the
presence of a pro-motility matrix in our two independent HK
migration assays and could not detect a significant pro-
motility effect. In addition, in the previously published
experiments, cell migration and cell division were not clearly
separated as distinct biological events, because no inhibitor
of mitogenesis was used in their migration assays.
HGF/scatter factor has also been reported to stimulate
mitosis and cell migration of HKs (Matsumoto et al., 1991). It
is thought that the mechanism by which HGF/scatter factor
promotes cellular migration is via a ERK kinase 1/ERK1-
mediated production of a gelatinase, matrix metalloprotei-
nase MMP-9 (McCawley et al., 1998; Zeigler et al., 1999).
Indeed, we and others showed that the expression of HK-
derived MMPs is linked to HK motility on collagen (Woodley
et al., 1986; Petersen et al., 1990, 1992; Sarret et al., 1992).
Nevertheless, in our two independent motility assays, we
could not detect a significant pro-motility HK effect by the
presence of HGF/scatter factor under serum-free conditions.
One possibility for this discrepancy is the short-term nature of
our assays and the adequate time for significant production of
MMP-9. We noticed that in previous studies, cell motility was
not clearly differentiated from cell proliferation, since their
migration assays were carried out without the presence of an
inhibitor of cell division. In the paper by McCawley et al.
(1998), the in vitro scratch assay was carried out for 48 hours
in the presence of a mitosis inhibitor. However, this assay
was three times longer than our 16-hour assay. The study by
Zeigler et al. (1999) was carried out in Boyden chambers,
which may favor more cell scattering and invasion than cell
motility. Lastly, none of these studies quantitatively com-
pared the effect of a given GF with HS.
Finally, our study has relevance for clinical medicine and
wound healing. In the unwounded state, epidermal keratino-
cytes are within an avascular epithelium and nourished by
plasma. When a wound occurs, these cells acutely experi-
ence serum for the first time and begin to migrate laterally to
close the wound. For many years, clinicians interested in
treating chronic, nonhealing wounds knew that transforming
a chronic wound into a new acute wound by surgical
manipulation would often jump start the wound to heal. We
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believe that it is possible that this new exposure of the cells in
the wound to serum and TGFa may be responsible for jump-
starting nonhealing wounds into wounds that heal.
MATERIALS AND METHODS
Primary HKs were purchased from Clonetics (San Diego, CA) and
cultured in the supplied EpiLife medium supplemented with human
keratinocyte growth supplements (HKGS) Kit (Cascade Biologics,
Portland, OR) as described previously (Henry et al., 2003; Li et al.,
2004b). Third or fourth passage of HKs cultures was used for all of
the experiments. HP and HS from donors with a variety of age and
genetic backgrounds were purchased from Sigma. Rat-tail type I
collagen was purchased from BD Biosciences (Bedford, MA).
Recombinant human TGFa, recombinant human IGF-1, recombi-
nant human IL-1a, recombinant human basic FGF, recombinant
human HB-EGF, porcine IL-8/CXCL8, and recombinant human TGF-
b1 were purchased from R&D Systems, Inc. (Minneapolis, MN).
Recombinant human EGF and recombinant human HGF were from
Sigma (St Louis, MO). Recombinant human insulin was from GIBCO
(Grand Island, NY). Recombinant human KGF was from ProSpec-
Tany TechnoGene Ltd (Rehovot, Israel). Poly-L-lysine (P-1274) and
colloidal gold (gold chloride, G4022) were purchased from Sigma.
Anti-human EGF antibody (MAB 236), anti-human IGF-1 antibody
(PR08), and anti-TGFa antibody (AF-239-NA) and anti-human HB-
EGF antibody (AF-259-NA) were purchased from R&D Systems, Inc.
Anti-insulin antibody (IN-05) was purchased from BioVendor
Laboratory Medicine (Palackeho, Czech Republic). Anti-phospho-
ERK1/2 antibody (V803A) was purchased from Promega (Madison,
WI). Anti-phospho-Samd2 (ser465/467) antibody (AB3849) was from
Chemicon International (Temecula, CA). All other reagents, unless
indicated, were either from VWR (West Chester, PA) or Sigma.
Colloidal gold migration assay
In order to assess keratinocyte motility without the confounding
problem of cell division, a short-term migration assay was used
according to the method of Albrecht-Buehler (Albrecht-Buehler,
1977) as modified by Woodley et al. (1988). The concentrations of
ECMs used to coat gold particles immobilized on coverslips were
optimized according to Li et al. (2004b). Experiments were
performed in triplicate, in which five nonoverlapping fields were
analyzed in three separate dishes. Computer-assisted morphometry
determined the area of each microscopic field consumed by the sum
of all the single-cell migration tracks in the field. The percentage of
the microscopic field consumed by migration tracks was termed an
MI.
The methodology to determine statistical differences in MIs
between experiments has previously been published (Chen et al.,
1993). In brief, statistical analyses of the MIs between triplicate sets
of experimental conditions were performed using Microsoft Excel.
All data were expressed as means 7 SE of separate experiments.
Differences between means were determined by Student t-test for
unpaired samples. Only those at Po0.05 were considered sig-
nificant, and the differences at P40.05 were insignificant.
In vitro wound-healing assay
A modified procedure of the in vitro wound-healing (scratch) assay
was performed according to Li et al. (2004b). The main modifi-
cations include: (1) coating the surface of the tissue culture plates or
glass coverslips with ECMs or nonmotile polylysine prior to plating
cells and (2) the wounds/scratches were made shortly after the cells
attached (within 2–3 hours). The precoated ECM and the relatively
short-cell attachment period prevented additional ECM deposition
on the migratory surface contributed by the cells themselves.
Mitomycin C (10 mg/ml) was included throughout the experiments
to prevent cell proliferation.
Pre-test of neutralizing antibodies
Based on the technical data on each antibody provided by the
manufacturers, we carried out titration experiments in order to
obtain the minimum concentration of each antibody that maximally
blocked the effect of the GF at a given concentration. Our results
were consistent with the tested data of these antibodies from the
manufacturers. We also tested if a given antibody crossreacted with
other HK pro-motility GFs, among TGFa, EGF, insulin, and IGF-1. To
achieve the maximum neutralizing effects, HS-containing media was
preincubated with the corresponding antibodies for 30 minutes prior
to being added to the cells in migration wells.
Immunoprecipitation with neutralizing antibodies
To predeplete TGFa or insulin from HS, 1.5 ml of serum (10%)-
containing media was incubated with indicated amounts (shown in
the figure) of a specific antibody overnight at 41C, that is, goat anti-
TGFa antibody (R&D, AF-239-NA) and mouse anti-insulin antibody
(BioVendor Laboratory Medicine, IN-05), negative control normal
goat IgG (AB-108-C, R&D Systems) and mouse IgG (IC002A, R&D
Systems). Since protein G may not bind to subtypes of IgG molecules
other than from rabbits with a high affinity, a secondary antibody
(5mg/ml rabbit anti-goat (ab7127, NOVUS Biologicals) or 25 mg/ml
rabbit anti-mouse (61–0100, Invitrogen) was added and incubated
for an additional 2 hours. The antigen–antibody complexes were
precipitated by incubation with protein G-Sepharose beads (25 ml of
presoaked and packed beads; maximum capacity,B250 mg of rabbit
IgG). The TGFa or insulin-depleted HS-containing media were then
tested in migration assays, in comparison to original and negative
control antibody-incubated serum-containing media.
All the above studies have USC institutional approval and
adherence to the Declaration of Helsinki Principles.
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